Skip to content

Lung adenocarcinoma — master bibliography

Last audited: 2026-08-29

Method. This ledger was regenerated from the ## References sections of all 18 canonical wiki pages and the guideline registry after every PMID had been resolved through live PubMed E-utilities queries in the 2026-08-29 audit session. One PMID appears once, under the first relevant topic in canonical page order; cited by records every wiki page that uses it, while guideline-registry-only records are labelled explicitly.

Foundations and overview

Epidemiology And Risk Factors

Histology And Classification

  • Tang Y, et al. The 2011 IASLC/ATS/ERS pulmonary adenocarcinoma classification: a landmark in personalized medicine for lung cancer management. J Thorac Dis. 2014. PMID 25349710 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md
  • Lee HJ, et al. IASLC/ATS/ERS International Multidisciplinary Classification of Lung Adenocarcinoma: novel concepts and radiologic implications. J Thorac Imaging. 2012. PMID 23086014 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md
  • Okada M, et al. Subtyping lung adenocarcinoma according to the novel 2011 IASLC/ATS/ERS classification: correlation with patient prognosis. Thorac Surg Clin. 2013. PMID 23566969 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md
  • Behera M, et al. Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. Clin Lung Cancer. 2016. PMID 27137345 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md, staging.md
  • Nakamura H, et al. Clinical impact of the new IASLC/ATS/ERS lung adenocarcinoma classification for chest surgeons. Surg Today. 2015. PMID 25417186 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md
  • Nicholson AG, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol. 2022. PMID 34808341 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md, molecular-landscape.md, molecular-testing.md
  • Sasaki T, et al. 2021 WHO Classification of Lung Cancer: Molecular Biology Research and Radiologic-Pathologic Correlation. Radiographics. 2024. PMID 38358935 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md
  • Frankell AM, et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023. PMID 37046096 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: overview.md, histology-and-classification.md, staging.md, molecular-landscape.md, molecular-testing.md, egfr-disease.md, biomarkers.md
  • Hou LK, et al. [Application of the WHO Classification of Thoracic Tumors (2021) grading system in invasive pulmonary adenocarcinoma and its correlation with the targeted genes' variations]. Zhonghua Bing Li Xue Za Zhi. 2023. PMID 36748132 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md
  • Yotsukura M, et al. Long-Term Prognosis of Patients With Resected Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma of the Lung. J Thorac Oncol. 2021. PMID 33915249 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md, staging.md, early-stage-and-perioperative-therapy.md
  • Zhang Y, et al. Surgery for pre- and minimally invasive lung adenocarcinoma. J Thorac Cardiovasc Surg. 2022. PMID 33485660 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md
  • Ito M, et al. Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma. Thorac Cancer. 2018. PMID 30298562 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md
  • Zhu J, et al. Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma. Cancer Med. 2023. PMID 36325966 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md
  • Zheng S, et al. Sublobar resection for adenocarcinoma in situ and minimally invasive adenocarcinoma diagnosed by intraoperative frozen section (ECTOP-1019): a study protocol of prospective, single-arm, multicenter, phase III study. J Thorac Dis. 2024. PMID 39444881 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md
  • Chen D, et al. Tumor Spread Through Air Spaces in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Ann Thorac Surg. 2019. PMID 30914285 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md, staging.md, early-stage-and-perioperative-therapy.md, biomarkers.md
  • Yin Q, et al. Meta-analysis of association between CT-based features and tumor spread through air spaces in lung adenocarcinoma. J Cardiothorac Surg. 2020. PMID 32912289 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md
  • Gu Y, et al. Computed Tomography Features and Tumor Spread Through Air Spaces in Lung Adenocarcinoma: A Meta-analysis. J Thorac Imaging. 2023. PMID 36583661 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md
  • Liu C, et al. Predictive value of multiple imaging predictive models for spread through air spaces of lung adenocarcinoma: A systematic review and network meta‑analysis. Oncol Lett. 2024. PMID 38348387 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md
  • Hegedűs F, et al. Prognostic impact of the IASLC grading system of lung adenocarcinoma: a systematic review and meta-analysis. Histopathology. 2024. PMID 38485464 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md, biomarkers.md
  • Wang S, et al. Proposed novel grading system for stage I invasive lung adenocarcinoma and a comparison with the 2020 IASLC grading system. Thorac Cancer. 2024. PMID 38273667 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md
  • Zhang Y, et al. Validation of the novel International Association for the Study of Lung Cancer grading system and prognostic value of filigree micropapillary and discohesive growth pattern in invasive pulmonary adenocarcinoma. Lung Cancer. 2023. PMID 36481678 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md
  • Rokutan-Kurata M, et al. Validation Study of the International Association for the Study of Lung Cancer Histologic Grading System of Invasive Lung Adenocarcinoma. J Thorac Oncol. 2021. PMID 33905897 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md, molecular-landscape.md, biomarkers.md
  • Chang WC, et al. Pulmonary invasive mucinous adenocarcinoma. Histopathology. 2024. PMID 37867404 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md, molecular-landscape.md, molecular-testing.md
  • Kuhn E, et al. Adenocarcinoma classification: patterns and prognosis. Pathologica. 2018. PMID 30259909 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md
  • Shen F, et al. Prognostic factors for resected invasive mucinous lung adenocarcinoma: a systematic review and meta-analysis. BMC Cancer. 2024. PMID 39455981 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md
  • Masago K, et al. Genomic Landscape of Resected Invasive Mucinous Adenocarcinoma of the Lung. Clin Lung Cancer. 2025. PMID 40634197 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md, molecular-landscape.md
  • Wang K, et al. A pretreatment prediction model of grade 3 tumors classed by the IASLC grading system in lung adenocarcinoma. BMC Pulm Med. 2023. PMID 37805451 — tags: [lung-adenocarcinoma, histology-and-classification] — cited by: histology-and-classification.md

Screening And Early Detection

  • National Lung Screening Trial Research Team, et al. The National Lung Screening Trial: overview and study design. Radiology. 2011. PMID 21045183 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • National Lung Screening Trial Research Team, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013. PMID 23697514 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Adams SJ, et al. Lung cancer screening. Lancet. 2023. PMID 36563698 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Walter JE, et al. Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study. Thorax. 2019. PMID 30591535 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Bonney A, et al. Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality. Cochrane Database Syst Rev. 2022. PMID 35921047 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Hunger T, et al. Lung Cancer Screening with Low-Dose CT in Smokers: A Systematic Review and Meta-Analysis. Diagnostics (Basel). 2021. PMID 34198856 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Usman Ali M, et al. Screening for lung cancer: A systematic review and meta-analysis. Prev Med. 2016. PMID 27130532 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Toumazis I, et al. Risk Model-Based Lung Cancer Screening : A Cost-Effectiveness Analysis. Ann Intern Med. 2023. PMID 36745885 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Senthil P, et al. Update on Lung Cancer Screening Guideline. Thorac Surg Clin. 2023. PMID 37806735 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Lee JH, et al. Deep Learning to Optimize Candidate Selection for Lung Cancer CT Screening: Advancing the 2021 USPSTF Recommendations. Radiology. 2022. PMID 35699582 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Vogel-Claussen J, et al. Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study. Lancet Oncol. 2025. PMID 41232542 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Frick C, et al. Risk-Adapted Lung Cancer Screening Starting Ages for Former Smokers. JAMA Netw Open. 2025. PMID 41632141 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Nam JG, et al. Evaluation and Management of Indeterminate Pulmonary Nodules on Chest Computed Tomography in Asymptomatic Subjects: The Principles of Nodule Guidelines. Semin Respir Crit Care Med. 2022. PMID 35803268 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Milleron B, et al. [Lung screening]. Rev Pneumol Clin. 2017. PMID 27956083 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Reid MJ, et al. Examining implementation strategies to reduce disparities in lung cancer screening uptake by state Medicaid expansion status: a scoping review. Prev Oncol Epidemiol. 2025. PMID 42038935 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Castañeda-Avila MA, et al. Lung Cancer Screening Eligibility, Uptake, and Adherence in Puerto Rico, 2022. JTO Clin Res Rep. 2025. PMID 40612588 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Williams LB, et al. Using Implementation Science to Disseminate a Lung Cancer Screening Education Intervention Through Community Health Workers. J Community Health. 2021. PMID 32594413 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Pandey S, et al. Common Determinants of Lung Cancer Screening Uptake in Three High-Risk and Underserved Communities. J Am Coll Radiol. 2025. PMID 41338709 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Moldovanu D, et al. Lung cancer screening and smoking cessation efforts. Transl Lung Cancer Res. 2021. PMID 33718048 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Pedersen JH, et al. Smoking cessation and lung cancer screening. Ann Transl Med. 2016. PMID 27195275 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Iaccarino JM, et al. Combining smoking cessation interventions with LDCT lung cancer screening: A systematic review. Prev Med. 2019. PMID 30753860 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Shen H, et al. Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer. BMC Med. 2022. PMID 36514063 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md, molecular-testing.md
  • Casagrande GMS, et al. Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs. Int J Mol Sci. 2023. PMID 36768828 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md, molecular-testing.md
  • Nguyen VTC, et al. Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization. Elife. 2023. PMID 37819044 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md
  • Wang Z, et al. Early detection and stratification of lung cancer aided by a cost-effective assay targeting circulating tumor DNA (ctDNA) methylation. Respir Res. 2023. PMID 37330511 — tags: [lung-adenocarcinoma, screening-and-early-detection] — cited by: screening-and-early-detection.md

Staging

  • Detterbeck FC, et al. The Proposed Ninth Edition TNM Classification of Lung Cancer. Chest. 2024. PMID 38885896 — tags: [lung-adenocarcinoma, staging] — cited by: overview.md, staging.md, early-stage-and-perioperative-therapy.md, guidelines.md
  • Rami-Porta R, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024. PMID 38447919 — tags: [lung-adenocarcinoma, staging] — cited by: overview.md, staging.md, early-stage-and-perioperative-therapy.md, guidelines.md
  • Klug M, et al. Proposed Ninth Edition TNM Staging System for Lung Cancer: Guide for Radiologists. Radiographics. 2024. PMID 39541244 — tags: [lung-adenocarcinoma, staging] — cited by: staging.md
  • Travis WD, et al. The International Association for the Study of Lung Cancer (IASLC) Staging Project for Lung Cancer: Recommendation to Introduce Spread Through Air Spaces as a Histologic Descriptor in the Ninth Edition of the TNM Classification of Lung Cancer. Analysis of 4061 Pathologic Stage I NSCLC. J Thorac Oncol. 2024. PMID 38508515 — tags: [lung-adenocarcinoma, staging] — cited by: staging.md, biomarkers.md
  • Asamura H, et al. IASLC Lung Cancer Staging Project: The New Database to Inform Revisions in the Ninth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2023. PMID 36773775 — tags: [lung-adenocarcinoma, staging] — cited by: staging.md
  • Fong KM, et al. The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024. PMID 38320664 — tags: [lung-adenocarcinoma, staging] — cited by: staging.md
  • Hwang JK, et al. Validation of the Eighth Edition TNM Lung Cancer Staging System. J Thorac Oncol. 2020. PMID 31863848 — tags: [lung-adenocarcinoma, staging] — cited by: staging.md
  • Sui X, et al. Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2017. PMID 28782726 — tags: [lung-adenocarcinoma, staging] — cited by: staging.md
  • Chansky K, et al. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2017. PMID 28461257 — tags: [lung-adenocarcinoma, staging] — cited by: staging.md
  • Detterbeck FC, et al. The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2016. PMID 27448762 — tags: [lung-adenocarcinoma, staging] — cited by: staging.md
  • Riihimäki M, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014. PMID 25130083 — tags: [lung-adenocarcinoma, staging] — cited by: staging.md
  • Wang H, et al. Occurrence and prognosis of lung cancer metastasis to major organs: a population-based study. Eur J Cancer Prev. 2023. PMID 36896839 — tags: [lung-adenocarcinoma, staging] — cited by: staging.md
  • Gomez DR, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019. PMID 31067138 — tags: [lung-adenocarcinoma, staging] — cited by: staging.md, systemic-therapy.md
  • Gomez DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016. PMID 27789196 — tags: [lung-adenocarcinoma, staging] — cited by: staging.md
  • Iyengar P, et al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018. PMID 28973074 — tags: [lung-adenocarcinoma, staging] — cited by: staging.md, systemic-therapy.md
  • Palma DA, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020. PMID 32484754 — tags: [lung-adenocarcinoma, staging] — cited by: staging.md
  • Palma DA, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019. PMID 30982687 — tags: [lung-adenocarcinoma, staging] — cited by: staging.md

Molecular Landscape

  • Zhang T, et al. Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma. Nature. 2026. PMID 41372401 — tags: [lung-adenocarcinoma, molecular-landscape] — cited by: molecular-landscape.md
  • Leal LF, et al. Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations. Sci Rep. 2019. PMID 30824880 — tags: [lung-adenocarcinoma, molecular-landscape] — cited by: molecular-landscape.md
  • Gimbrone NT, et al. Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients. J Thorac Oncol. 2017. PMID 28911955 — tags: [lung-adenocarcinoma, molecular-landscape] — cited by: molecular-landscape.md
  • Li X, et al. Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific. BMC Pulm Med. 2023. PMID 36964522 — tags: [lung-adenocarcinoma, molecular-landscape] — cited by: molecular-landscape.md
  • Ci B, et al. Molecular differences across invasive lung adenocarcinoma morphological subgroups. Transl Lung Cancer Res. 2020. PMID 32953482 — tags: [lung-adenocarcinoma, molecular-landscape] — cited by: molecular-landscape.md
  • Hobor S, et al. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Nat Commun. 2024. PMID 38871738 — tags: [lung-adenocarcinoma, molecular-landscape] — cited by: molecular-landscape.md, egfr-disease.md, immunotherapy.md, systemic-therapy.md
  • Biswas D, et al. Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma. Nat Cancer. 2025. PMID 39789179 — tags: [lung-adenocarcinoma, molecular-landscape] — cited by: molecular-landscape.md
  • Pan X, et al. The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma. Nat Cancer. 2024. PMID 38200244 — tags: [lung-adenocarcinoma, molecular-landscape] — cited by: molecular-landscape.md, biomarkers.md
  • Lavin Y, et al. Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell. 2017. PMID 28475900 — tags: [lung-adenocarcinoma, molecular-landscape] — cited by: molecular-landscape.md, biomarkers.md
  • Sinjab A, et al. Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. Cancer Discov. 2021. PMID 33972311 — tags: [lung-adenocarcinoma, molecular-landscape] — cited by: molecular-landscape.md, biomarkers.md
  • Wang C, et al. The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing. Signal Transduct Target Ther. 2022. PMID 36008393 — tags: [lung-adenocarcinoma, molecular-landscape] — cited by: molecular-landscape.md
  • Zhao W, et al. A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma. Nat Cancer. 2025. PMID 41057692 — tags: [lung-adenocarcinoma, molecular-landscape] — cited by: molecular-landscape.md

Molecular Testing

  • Kalemkerian GP, et al. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol. 2018. PMID 29401004 — tags: [lung-adenocarcinoma, molecular-testing] — cited by: molecular-testing.md
  • Leighl NB, et al. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res. 2019. PMID 30988079 — tags: [lung-adenocarcinoma, molecular-testing] — cited by: molecular-testing.md, egfr-disease.md, kras-braf-met-her2.md, systemic-therapy.md, biomarkers.md
  • Rolfo C, et al. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol. 2018. PMID 29885479 — tags: [lung-adenocarcinoma, molecular-testing] — cited by: molecular-testing.md
  • Rolfo C, et al. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021. PMID 34246791 — tags: [lung-adenocarcinoma, molecular-testing] — cited by: molecular-testing.md, egfr-disease.md, alk-ros1-and-fusion-drivers.md, kras-braf-met-her2.md, immunotherapy.md, systemic-therapy.md, biomarkers.md
  • de Jager VD, et al. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries. Lancet Reg Health Eur. 2024. PMID 38476742 — tags: [lung-adenocarcinoma, molecular-testing] — cited by: molecular-testing.md
  • Yu TM, et al. Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non-Small-cell Lung Cancer: A Single-center Analysis. Clin Lung Cancer. 2019. PMID 30243889 — tags: [lung-adenocarcinoma, molecular-testing] — cited by: molecular-testing.md, alk-ros1-and-fusion-drivers.md, kras-braf-met-her2.md
  • Anand K, et al. Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma. Clin Lung Cancer. 2020. PMID 32600793 — tags: [lung-adenocarcinoma, molecular-testing] — cited by: molecular-testing.md, guidelines.md
  • Lim C, et al. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Ann Oncol. 2015. PMID 25922063 — tags: [lung-adenocarcinoma, molecular-testing] — cited by: molecular-testing.md
  • Pritchett MA, et al. Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019. PMID 32914040 — tags: [lung-adenocarcinoma, molecular-testing] — cited by: molecular-testing.md, biomarkers.md
  • Uemura T, et al. Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L. Cancer Med. 2023. PMID 37948122 — tags: [lung-adenocarcinoma, molecular-testing] — cited by: molecular-testing.md
  • Aggarwal C, et al. Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023. PMID 37499192 — tags: [lung-adenocarcinoma, molecular-testing] — cited by: molecular-testing.md, patient-experience-and-advocacy.md
  • Thompson JC, et al. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. Clin Cancer Res. 2016. PMID 27601595 — tags: [lung-adenocarcinoma, molecular-testing] — cited by: molecular-testing.md
  • Gray J, et al. Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer. Oncologist. 2021. PMID 34216176 — tags: [lung-adenocarcinoma, molecular-testing] — cited by: molecular-testing.md
  • Kalemkerian GP, et al. Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Oncol Pract. 2018. PMID 29589987 — tags: [lung-adenocarcinoma, molecular-testing] — cited by: molecular-testing.md
  • Moore DA, et al. Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer. Lung Cancer. 2021. PMID 34536732 — tags: [lung-adenocarcinoma, molecular-testing] — cited by: molecular-testing.md
  • Garinet S, et al. Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practice. Pathology. 2024. PMID 38834439 — tags: [lung-adenocarcinoma, molecular-testing] — cited by: molecular-testing.md

Egfr Disease

  • Ramalingam SS, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020. PMID 31751012 — tags: [lung-adenocarcinoma, egfr-disease] — cited by: egfr-disease.md, systemic-therapy.md
  • Planchard D, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023. PMID 37937763 — tags: [lung-adenocarcinoma, egfr-disease] — cited by: egfr-disease.md, systemic-therapy.md
  • Cho BC, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024. PMID 38924756 — tags: [lung-adenocarcinoma, egfr-disease] — cited by: egfr-disease.md, systemic-therapy.md
  • Tsuboi M, et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023. PMID 37272535 — tags: [lung-adenocarcinoma, egfr-disease] — cited by: egfr-disease.md, early-stage-and-perioperative-therapy.md, guidelines.md, red-flags-and-safety-concerns.md
  • Mok TS, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017. PMID 27959700 — tags: [lung-adenocarcinoma, egfr-disease] — cited by: egfr-disease.md, systemic-therapy.md
  • Zhou C, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023. PMID 37870976 — tags: [lung-adenocarcinoma, egfr-disease] — cited by: egfr-disease.md, systemic-therapy.md, clinical-trials-landscape.md
  • Roper N, et al. Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer. Cell Rep Med. 2020. PMID 32483558 — tags: [lung-adenocarcinoma, egfr-disease] — cited by: egfr-disease.md
  • Cho BC, et al. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncol. 2022. PMID 34911336 — tags: [lung-adenocarcinoma, egfr-disease] — cited by: egfr-disease.md
  • Felip E, et al. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Ann Oncol. 2024. PMID 38942080 — tags: [lung-adenocarcinoma, egfr-disease] — cited by: egfr-disease.md, systemic-therapy.md, red-flags-and-safety-concerns.md
  • Brown H, et al. Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. J Thorac Oncol. 2020. PMID 31605792 — tags: [lung-adenocarcinoma, egfr-disease] — cited by: egfr-disease.md
  • Papadimitrakopoulou VA, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020. PMID 32861806 — tags: [lung-adenocarcinoma, egfr-disease] — cited by: egfr-disease.md
  • Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014. PMID 24893891 — tags: [lung-adenocarcinoma, egfr-disease] — cited by: egfr-disease.md
  • Thress KS, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015. PMID 25939061 — tags: [lung-adenocarcinoma, egfr-disease] — cited by: egfr-disease.md

Alk Ros1 And Fusion Drivers

Kras Braf Met Her2

Immunotherapy

  • Skoulidis F, et al. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024. PMID 39385035 — tags: [lung-adenocarcinoma, immunotherapy, STK11, KEAP1] — cited by: kras-braf-met-her2.md, immunotherapy.md, biomarkers.md

  • Socinski MA, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018. PMID 29863955 — tags: [lung-adenocarcinoma, immunotherapy] — cited by: immunotherapy.md, systemic-therapy.md

  • Reck M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019. PMID 30922878 — tags: [lung-adenocarcinoma, immunotherapy] — cited by: immunotherapy.md
  • Nogami N, et al. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. J Thorac Oncol. 2022. PMID 34626838 — tags: [lung-adenocarcinoma, immunotherapy] — cited by: immunotherapy.md
  • Paz-Ares LG, et al. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. J Thorac Oncol. 2022. PMID 34648948 — tags: [lung-adenocarcinoma, immunotherapy] — cited by: immunotherapy.md, biomarkers.md
  • Reck M, et al. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial. Eur J Cancer. 2024. PMID 39270380 — tags: [lung-adenocarcinoma, immunotherapy] — cited by: immunotherapy.md
  • Kilickap S, et al. Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1. J Thorac Oncol. 2025. PMID 40118215 — tags: [lung-adenocarcinoma, immunotherapy] — cited by: immunotherapy.md
  • Gadgeel SM, et al. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. J Thorac Oncol. 2024. PMID 38642841 — tags: [lung-adenocarcinoma, immunotherapy] — cited by: immunotherapy.md
  • Lisberg A, et al. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. J Thorac Oncol. 2018. PMID 29874546 — tags: [lung-adenocarcinoma, immunotherapy] — cited by: immunotherapy.md, red-flags-and-safety-concerns.md
  • Scalera S, et al. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy. J Thorac Oncol. 2021. PMID 34450259 — tags: [lung-adenocarcinoma, immunotherapy] — cited by: immunotherapy.md
  • Scalera S, et al. Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma. Ann Oncol. 2023. PMID 36526124 — tags: [lung-adenocarcinoma, immunotherapy] — cited by: immunotherapy.md, biomarkers.md
  • Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021. PMID 34724392 — tags: [lung-adenocarcinoma, immunotherapy] — cited by: immunotherapy.md, red-flags-and-safety-concerns.md
  • Nishino M, et al. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res. 2016. PMID 27535979 — tags: [lung-adenocarcinoma, immunotherapy] — cited by: immunotherapy.md, red-flags-and-safety-concerns.md
  • Palaskas N, et al. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc. 2020. PMID 31960755 — tags: [lung-adenocarcinoma, immunotherapy] — cited by: immunotherapy.md, red-flags-and-safety-concerns.md
  • Raikhelkar J, et al. Immune checkpoint inhibitor myocarditis. Curr Opin Cardiol. 2019. PMID 30925516 — tags: [lung-adenocarcinoma, immunotherapy] — cited by: immunotherapy.md, red-flags-and-safety-concerns.md
  • Vogelbaum MA, et al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol. 2022. PMID 34932393 — tags: [lung-adenocarcinoma, immunotherapy] — cited by: immunotherapy.md, systemic-therapy.md, guidelines.md, red-flags-and-safety-concerns.md

Early Stage And Perioperative Therapy

Systemic Therapy

Biomarkers

  • Abbosh C, et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023. PMID 37055640 — tags: [lung-adenocarcinoma, biomarkers] — cited by: biomarkers.md
  • Wang K, et al. Adjuvant osimertinib therapy guided by ctDNA-assessed MRD in resected EGFR-mutated stage IA-IIA non-small-cell lung cancer: a randomized clinical trial study protocol. Am J Cancer Res. 2024. PMID 39659920 — tags: [lung-adenocarcinoma, biomarkers, MRD, protocol] — cited by: biomarkers.md, OPEN-QUESTIONS.md
  • Andersen ME, et al. ctDNA guided immunotherapy in patients with advanced non-small cell lung cancer: a nationwide Danish, randomised, intervention study (PRELUCA) — study protocol. BMJ Open. 2026. PMID 41628935 — tags: [lung-adenocarcinoma, biomarkers, ctDNA, protocol] — cited by: biomarkers.md, OPEN-QUESTIONS.md

Guidelines

  • Wheatley Price P, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3. J Clin Oncol. 2026. PMID 42607282 — tags: [lung-adenocarcinoma, guidelines, driver-alterations] — cited by: guidelines.md
  • Reuss JE, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.1. J Clin Oncol. 2026. PMID 42190143 — tags: [lung-adenocarcinoma, guidelines, driver-alterations] — cited by: guidelines.md
  • Bazhenova L, et al. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2026.3.1. J Clin Oncol. 2026. PMID 42190141 — tags: [lung-adenocarcinoma, guidelines, driver-negative] — cited by: guidelines.md
  • Mahmood K, et al. Management of Central Airway Obstruction: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2025. PMID 39029785 — tags: [lung-adenocarcinoma, guidelines, airway-obstruction] — cited by: guideline registry

  • El-Hajj Fuleihan G, et al. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2023. PMID 36545746 — tags: [lung-adenocarcinoma, guidelines, hypercalcemia] — cited by: guideline registry

  • Sholl LM, et al. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation. Arch Pathol Lab Med. 2024. PMID 38625026 — tags: [lung-adenocarcinoma, guidelines] — cited by: guidelines.md

  • Daly ME, et al. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. J Clin Oncol. 2022. PMID 34936470 — tags: [lung-adenocarcinoma, guidelines] — cited by: guidelines.md
  • Wolf AMD, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2024. PMID 37909877 — tags: [lung-adenocarcinoma, guidelines] — cited by: guidelines.md
  • Videtic GMM, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017. PMID 28596092 — tags: [lung-adenocarcinoma, guidelines] — cited by: guidelines.md
  • Iyengar P, et al. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline. Pract Radiat Oncol. 2023. PMID 37294262 — tags: [lung-adenocarcinoma, guidelines] — cited by: guidelines.md

Clinical Trials Landscape

  • Waterhouse DM, et al. Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation. Lung Cancer. 2024. PMID 39303400 — tags: [lung-adenocarcinoma, clinical-trials-landscape] — cited by: clinical-trials-landscape.md

Patient Experience And Advocacy

  • Maguire R, et al. Lung cancer stigma: A concept with consequences for patients. Cancer Rep (Hoboken). 2019. PMID 32721137 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Williamson TJ, et al. Lung Cancer Stigma: Does Smoking History Matter? Ann Behav Med. 2020. PMID 31942920 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Ostroff JS, et al. Lung cancer stigma and depression: Validation of the Lung Cancer Stigma Inventory. Psychooncology. 2019. PMID 30779396 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Carter-Harris L, et al. Lung cancer stigma predicts timing of medical help-seeking behavior. Oncol Nurs Forum. 2014. PMID 24769603 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Shen MJ, et al. Association between patient-provider communication and lung cancer stigma. Support Care Cancer. 2016. PMID 26553030 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • McDonnell KK, et al. The association between lung cancer stigma and race: A descriptive correlational study. Health Expect. 2022. PMID 35415934 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Occhipinti S, et al. Lung Cancer Stigma across the Social Network: Patient and Caregiver Perspectives. J Thorac Oncol. 2018. PMID 29981928 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Tod AM, et al. Diagnostic delay in lung cancer: a qualitative study. J Adv Nurs. 2008. PMID 18197868 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Otty Z, et al. Patient and carer experiences of lung cancer referral pathway in a regional health service: a qualitative study. Intern Med J. 2023. PMID 36710377 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Morrison EJ, et al. Emotional Problems, Quality of Life, and Symptom Burden in Patients With Lung Cancer. Clin Lung Cancer. 2017. PMID 28412094 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Yang P, et al. Quality of life and symptom burden among long-term lung cancer survivors. J Thorac Oncol. 2012. PMID 22134070 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Bouazza YB, et al. Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic review. Lung Cancer. 2017. PMID 29110842 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Dai W, et al. Patient-Reported Outcome-Based Symptom Management Versus Usual Care After Lung Cancer Surgery: A Multicenter Randomized Controlled Trial. J Clin Oncol. 2022. PMID 34995100 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Melzer AC, et al. What Exactly Is Shared Decision-Making? A Qualitative Study of Shared Decision-Making in Lung Cancer Screening. J Gen Intern Med. 2020. PMID 31745852 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Lee YH, et al. Trajectories of caregiver burden and related factors in family caregivers of patients with lung cancer. Psychooncology. 2018. PMID 29476636 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Zhu S, et al. Caregiver burden for informal caregivers of patients after surgical treatment of early-stage lung cancer. J Clin Nurs. 2023. PMID 35869414 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • He Y, et al. Sleep quality, anxiety and depression in advanced lung cancer: patients and caregivers. BMJ Support Palliat Care. 2022. PMID 32253349 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Friedes C, et al. Longitudinal Trends of Financial Toxicity in Patients With Lung Cancer: A Prospective Cohort Study. JCO Oncol Pract. 2021. PMID 33555936 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Takemura N, et al. Financial hardship experience in middle- and older-aged patients with advanced lung cancer. Support Care Cancer. 2024. PMID 38775918 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Hsu ML, et al. Unmet Needs, Quality of Life, and Financial Toxicity Among Survivors of Lung Cancer. JAMA Netw Open. 2024. PMID 38630475 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Patel MI, et al. Perspectives of Low-Income and Minority Populations With Lung Cancer: A Qualitative Evaluation of Unmet Needs. JCO Oncol Pract. 2022. PMID 35696628 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Curran WJ Jr, et al. Addressing the current challenges of non-small-cell lung cancer clinical trial accrual. Clin Lung Cancer. 2008. PMID 18650170 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Horn L, et al. Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. Clin Lung Cancer. 2013. PMID 22591607 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Mudaranthakam DP, et al. Barriers to Clinical Trial Participation: Comparative Study Between Rural and Urban Participants. JMIR Cancer. 2022. PMID 35451964 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
  • Cochrane A, et al. Unmet supportive care needs associated with quality of life for people with lung cancer: A systematic review of the evidence 2007-2020. Eur J Cancer Care (Engl). 2022. PMID 34729855 — tags: [lung-adenocarcinoma, patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md

Red Flags And Safety Concerns

  • O'Gurek D, et al. Hemoptysis: Evaluation and Management. Am Fam Physician. 2022. PMID 35166503 — tags: [lung-adenocarcinoma, red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
  • Davidson K, et al. Managing Massive Hemoptysis. Chest. 2020. PMID 31374211 — tags: [lung-adenocarcinoma, red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
  • Deshwal H, et al. Life-Threatening Hemoptysis. Semin Respir Crit Care Med. 2021. PMID 32862418 — tags: [lung-adenocarcinoma, red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
  • Cordovilla R, et al. Diagnosis and Treatment of Hemoptysis. Arch Bronconeumol. 2016. PMID 26873518 — tags: [lung-adenocarcinoma, red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
  • Feller-Kopman DJ, et al. Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline. Am J Respir Crit Care Med. 2018. PMID 30272503 — tags: [lung-adenocarcinoma, red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
  • Taylor JW, et al. Metastatic epidural spinal cord compression. Semin Neurol. 2010. PMID 20577931 — tags: [lung-adenocarcinoma, red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
  • Warnock C, et al. Improving care of patients with metastatic spinal cord compression. Br J Nurs. 2014. PMID 24619048 — tags: [lung-adenocarcinoma, red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
  • Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2023. PMID 37075273 — tags: [lung-adenocarcinoma, red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
  • Taplitz RA, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol. 2018. PMID 29461916 — tags: [lung-adenocarcinoma, red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
  • Voruganti Maddali IS, et al. Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study. Lung Cancer. 2024. PMID 38788551 — tags: [lung-adenocarcinoma, red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
  • Li S, et al. Neoadjuvant therapy and risk of bronchopleural fistula after lung cancer surgery: a systematic meta-analysis of 14 912 patients. Jpn J Clin Oncol. 2016. PMID 27052116 — tags: [lung-adenocarcinoma, red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
  • Endo S, et al. Risk assessments for broncho-pleural fistula and respiratory failure after lung cancer surgery by National Clinical Database Japan. Gen Thorac Cardiovasc Surg. 2019. PMID 30328066 — tags: [lung-adenocarcinoma, red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md

Ledger checks

  • Unique PMIDs: 262.
  • Canonical wiki pages scanned: 18.
  • Identifier rule: no PMID enters this ledger unless it occurs in a page reference section and resolved through PubMed in the current build session.
  • Scope rule: ClinicalTrials.gov records and non-journal organization sources live in their dedicated registries, not in this PubMed bibliography.